Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Study of Ketamine Administered Intravenously and by Sublingual Wafer

6 de marzo de 2015 actualizado por: iX Biopharma Ltd.

An Open Label, Two Way Crossover Study to Evaluate the Bioavailability and Clinical Tolerability of a Novel Sublingual Wafer Formulation of Ketamine in Healthy Male Volunteers

To determine the rate and extent of of absorption of racemic ketamine from sublingual wafer

Descripción general del estudio

Estado

Terminado

Condiciones

Descripción detallada

  1. To determine the apparent rate of disintegration of the sublingual wafer
  2. To determine the overall clinical tolerability of ketamine when administered as a single dose via the sublingual route. Tolerability will be assessed using a range of objective and subjective parameters as assessed using modified Likert and Bond and Lader scales.

Tipo de estudio

De observación

Inscripción (Actual)

8

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Pain and Anaesthesia Research Clinic (PARC), Royal Adelaide Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Masculino

Método de muestreo

Muestra de probabilidad

Población de estudio

8 Healthy Male Volunteers

Descripción

Inclusion Criteria:

  1. Adult males aged 18-65 years.
  2. Good general health without clinically significant renal, hepatic, cardiac or respiratory disease, as determined by the Principal Investigator.
  3. Good general mental health as determined by scores on the Symptom Checklist-90-R (SCL-90-R®), a screening instrument which evaluates a broad range of psychological problems and symptoms of psychopathology.
  4. Agree to and be capable of signing an Informed Consent Form.
  5. Have suitable venous access for blood sampling.
  6. BMI within the range of 19-30 kg/m2.

Exclusion Criteria:

  1. Renal impairment as evidenced by estimated creatinine clearance (CrCl), measured by the Cockcroft-Gault method, of less than 90 mL/min.
  2. Have a laboratory value at the Screening Visit that is outside the normal range, unless it is judged by the Investigator as not clinically significant after appropriate evaluation.
  3. A score of more than two standard deviations from the mean on any of the key nine scales in the SCL-90-R ®
  4. Any medical condition that in the opinion of the Investigator may adversely impact on the participant's ability to complete the study, including but not limited to:

    • History of cerebral trauma or stroke
    • History of seizure or epilepsy
    • Hyperthyroidism
    • Recent clinically significant URTI (within two weeks of Day 1) or respiratory infection
    • History of Myocardial Infarction or clinically significant cardiac disease including cardiac arrhythmia.
    • Poorly controlled hypertension - as assessed by the Principal Investigator.
    • Clinically significant history of asthma requiring regular supportive or preventative therapy (childhood asthma that has resolved >5 years previously may be suitable for inclusion at the discretion of the Investigator.
    • Glaucoma
  5. Plasma AST, ALT and ALP tests in excess of 1.5 times the upper limit of normal.
  6. History of severe allergic or anaphylactic drug-related reactions.
  7. History of hypersensitivity to ketamine or any of its excipients.
  8. Current (within the last six months) clinically significant psychiatric disorder including anxiety, psychosis or depression.
  9. Concurrent use of other medication on a regular or daily basis including but not limited to, theophylline, benzodiazepines, thyroxine, sedatives or anti-anxiolytics.
  10. Participation in another clinical trial of an investigational agent within 30 days of study entry.
  11. Known history of past or present infection with hepatitis C virus (HCV), hepatitis B or human immunodeficiency virus (HIV).
  12. Clinically significant abnormal ECG (12-lead) at the screening visit or prior to dosing on Day 1, as determined by the Investigator.
  13. Participants who have a marked prolongation of the QT corrected (QTc) interval (i.e., repeated demonstration of a QTc >430 msec for males) at screening or prior to dosing on Day 1 in either study period will not be allowed to continue in the study.
  14. Significant history of illicit drug or alcohol use or abuse (as determined by the Principal Investigator).
  15. Any alcohol use within 24 hours prior to dosing on Day 1 in each of the study periods.
  16. Unwillingness or inability to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the participant returning for follow-up visits on schedule.
  17. Blood donation (1 unit or more) within 1 month prior to the screening visit.
  18. Current or previous tobacco user (within 12 months prior to Day 1) .
  19. Planned surgical procedure requiring general anaesthesia during the study period and within two weeks of study completion

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Bioavailability of a single 25 mg dose of sublingual (SL) ketamine
Periodo de tiempo: 24 hours post-dose for two dosing periods, which were separated by 7 days.
Bioavailability determined by evaluation and comparison of PK variables following SL and IV administration.
24 hours post-dose for two dosing periods, which were separated by 7 days.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
General clinical tolerability and safety
Periodo de tiempo: 24 hours post-dose for two dosing periods, which were separated by 7 days.
Determined by using a range of objective and subjective parameters.
24 hours post-dose for two dosing periods, which were separated by 7 days.
Rate of disintegration
Periodo de tiempo: 5 minutes post-dose
Measured the apparent rate of disintegration of a single 25 mg sublingual wafer formulation of ketamine.
5 minutes post-dose

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Pual Rolan, Pain and Anaesthesia Research Clinic - PARC

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de junio de 2011

Finalización primaria (Actual)

1 de junio de 2011

Finalización del estudio (Actual)

1 de junio de 2011

Fechas de registro del estudio

Enviado por primera vez

19 de junio de 2011

Primero enviado que cumplió con los criterios de control de calidad

20 de junio de 2011

Publicado por primera vez (Estimar)

21 de junio de 2011

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

10 de marzo de 2015

Última actualización enviada que cumplió con los criterios de control de calidad

6 de marzo de 2015

Última verificación

1 de marzo de 2015

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • Ket001

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir